Clinical study for the detection of prostate cancer lesions using F-18-PSMA-1007 PET (Positron Emission Tomography)
Résumé de l'étude
In prostate cancer patients, an increase in the PSA (Prostate-Specific Antigen) blood level after prior prostate cancer treatment may be a sign of tumor recurrence. To localize the tumor, imaging procedures (such as computed tomography [CT], magnetic resonance imaging [MRI], or positron emission tomography [PET]) are routinely performed. In PET, radioactively labeled biomolecules, known as tracers, are used to visualize metabolic processes. In our research project, we want to find out how well the tracer F-18-PSMA-1007 detects prostate cancer lesions during a PET scan.
(BASEC)
Intervention étudiée
For this study, the patient must undergo 4 to 5 visits within 6 months.
During the first visit, patient data and medical history are recorded, and a blood and urine sample is taken to assess the patient's health status. The patient receives an injection of the tracer F-18-PSMA-1007 during the second visit, and a PET scan is performed. An ECG and vital signs are recorded before and after the injection / PET scan. Visit 3 takes place one day after visit 2, and blood and urine samples are again collected for a safety check. Some patients are invited to visit 4, during which either an MRI examination or a biopsy is performed. Whether a visit 4 is necessary for the patient depends on the stage of the prostate cancer and the results of the F-18-PSMA-1007 PET examination. The final visit, 6 months after the PET scan, is then necessary for all patients; here, further patient data on the disease progression since the start of the study is collected.
(BASEC)
Maladie en cours d'investigation
Prostate cancer
(BASEC)
Men diagnosed with prostate cancer can participate in the study. The prostate cancer has already been targeted treated, and there is suspicion of recurrence as the PSA blood level has increased again despite treatment. (BASEC)
Critères d'exclusion
Patients whose health status is not stable cannot participate. If they cannot tolerate the tracer F-18-PSMA-1007 in any way, they are excluded from the study. Other exclusion reasons include the inability to undergo a PET scan (e.g., due to severe obesity or claustrophobia) or participation in other clinical trials. (BASEC)
Lieu de l’étude
Berne
(BASEC)
Sponsor
ABX advanced biochemical compounds Radeberg, Germany Silvia Dotti-Sigrist Bottmingen Switzerland
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Ali Afshar-Oromieh
+41 31 632 36 55
ali.afshar@clutterinsel.chInselspital, Universitätsspital Bern Universitätsklinik für Nuklearmedizin Rosenbühlgasse 25 CH-3010 Bern
(BASEC)
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Commission cantonale d'éthique de Berne
(BASEC)
Date d'approbation du comité d'éthique
13.07.2021
(BASEC)
Identifiant de l'essai ICTRP
NCT04742361 (ICTRP)
Titre officiel (approuvé par le comité d'éthique)
Phase III study of [18F]PSMA-1007 positron emission tomography for the detection of prostate cancer lesions in patients with biochemical recurrence after previous definitive treatment for localized prostate cancer (BASEC)
Titre académique
Phase III Study of [18F]PSMA-1007 Positron Emission Tomography for the Detection of Prostate Cancer Lesions in Patients With Biochemical Recurrence After Previous Definitive Treatment for Localized Prostate Cancer (ICTRP)
Titre public
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer (ICTRP)
Maladie en cours d'investigation
Prostate CancerProstate Cancer Recurrent (ICTRP)
Intervention étudiée
Drug: [18F]PSMA-1007 (ICTRP)
Type d'essai
Interventional (ICTRP)
Plan de l'étude
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label). (ICTRP)
Critères d'inclusion/exclusion
Inclusion Criteria:
- Male with original diagnosis of adenocarcinoma of the prostate with prior definitive
therapy
- Suspicion of recurrence or persistence
- after radiotherapy or cryotherapy: 3 consecutive PSA rises and/or PSA rise by
2.0 ng/mL or more above nadir (ASTRO-Phoenix)
- after prostatectomy, PSA > 0.2 ng/mL on 2 or more determinations (recurrence),
or failure of PSA to fall to undetectable levels post-prostatectomy
(persistence) (American Urological Association)
- For patients who previously had radical prostatectomy, salvage radiotherapy is one
likely treatment plan for patients who initially underwent radiotherapy (including
brachytherapy), confirmation of low volume disease is needed to define (local)
treatment.
- Life expectancy of 6 months or more as judged by the investigator
- Willing and able to undergo all study procedures
- Informed consent in writing
Exclusion Criteria:
- Age: less than18 years
- Contraindications to any of the ingredients of [18F]PSMA-1007
- Close affiliation with the investigational site
- At the time of enrolment into this study, participating in another therapeutic
clinical trial or has completed study participation in another therapeutic clinical
trial within 5 days of enrolment into this trial
- Having been previously enrolled in this clinical trial
- Mental conditions rendering the subject incapable to understand the nature, scope,
and consequences of the trial
- Being clinically unstable or requiring emergency treatment
- Patients who are unwilling to consider a biopsy if clinically recommended
- Patients who are unable to undergo a PET/CT scan
- Patients for whom systemic therapy is the most likely course regardless of PET
findings. (ICTRP)
non disponible
Critères d'évaluation principaux et secondaires
Region-level positive predictive value (PPV) of [18F]PSMA-1007 using a combined standard of truth (SOT);Patient-level correct detection rate of [18F]PSMA-1007 (ICTRP)
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
Alexander Hoepping, Dr., hoepping@abx.de, +49 3528 4041 60 (ICTRP)
ID secondaires
ABX-CT-303 (ICTRP)
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
https://clinicaltrials.gov/study/NCT04742361 (ICTRP)
Résultats de l'essai
Résumé des résultats
laymens-studienreport-summary-ch-20250207.pdfLien vers les résultats dans le registre primaire
non disponible